DIRAS3 and ovarian cancer: We observed that ovarian cancer patients bearing a shallow deletion of MIR1305 together with high DIRAS3 expression display a significantly better overall survival compared to that observed in the group of patients with no CNV alterations (possibly expressing high MIR1305).